Search Results

23andMe Holding Co. and Nightingale Health Plc announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, released a new genetic Bipolar Disorder report for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and Exchange Commission.

Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024, which ended March 31, 2024.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer.

23andMe Holding Co. presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31-June 4.

23andMe Holding Co., a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance, the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community.

23andMe Holding Co., a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced that it will report financial results for the fourth quarter and full fiscal year 2024 after the market closes on Thursday, May 23, 2024.